JY
DCPH

Jeff Yass’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Jeff Yass’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,200
Closed -$184K – 13750
2022
Q4 		$184K Buy
+11,200
New +$182K ﹤0.01% 10256
2022
Q1 		– Sell
-105,000
Closed -$1.03M – 14220
2021
Q4 		$1.03M Buy
105,000
+87,800
+510% +$1.65M ﹤0.01% 7227
2021
Q3 		$584K Sell
17,200
-48,000
-74% -$1.53M ﹤0.01% 8971
2021
Q2 		$2.39M Buy
65,200
+9,500
+17% +$368K ﹤0.01% 5513
2021
Q1 		$2.5M Sell
55,700
-88,300
-61% -$4.11M ﹤0.01% 5379
2020
Q4 		$8.22M Buy
144,000
+14,600
+11% +$865K ﹤0.01% 2738
2020
Q3 		$6.64M Buy
129,400
+7,300
+6% +$358K ﹤0.01% 2715
2020
Q2 		$7.29M Buy
122,100
+59,900
+96% +$3.2M ﹤0.01% 2518
2020
Q1 		$2.56M Sell
62,200
-117,600
-65% -$6.53M ﹤0.01% 3539
2019
Q4 		$11.2M Buy
179,800
+27,300
+18% +$1.3M ﹤0.01% 1970
2019
Q3 		$5.18M Buy
152,500
+142,500
+1,425% +$4.22M ﹤0.01% 2679
2019
Q2 		$226K Buy
+10,000
New +$234K ﹤0.01% 8892

Other funds holding DCPH

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Jeff Yass's DCPH Position: Q2 2024 in Review

Jeff Yass sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 58,100 shares — an estimated $914K sold.

Jeff Yass first reported a position in DCPH in Q2 2018 and held it in 21 quarters. The position peaked at $5.08M in Q4 2019. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • Jeff Yass reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Jeff Yass sold 58,100 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $914K.
  • Jeff Yass first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 21 quarters.
  • Jeff Yass's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $5.08M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.